Literature DB >> 23053426

A prospective analysis of the incidence of and risk factors for opportunistic infections in patients with inflammatory bowel disease.

Makoto Naganuma1, Reiko Kunisaki, Naoki Yoshimura, Yoshiaki Takeuchi, Mamoru Watanabe.   

Abstract

BACKGROUND: Immunosuppressants lead to an increased risk of infection, but few prospective studies have assessed the incidence of opportunistic infections in inflammatory bowel disease (IBD) patients, a high proportion of whom are treated with immunosuppressants. The aim of this study was to assess the age distribution of Japanese IBD patients with opportunistic infections and the risk factors associated with these infections.
METHODS: A multicenter, prospective study of 570 IBD patients was conducted. The patients were followed for up to 12 months to identify any new infections. The incidence of opportunistic infections and the age distribution of patients with these infections were analyzed. We carried out a case-control study in which 2 non-infected IBD patients were selected as controls for each case (infected IBD patient); the effect of medications on the infection rate was also examined.
RESULTS: Fifty-two (9.1 %) of 570 IBD patients developed opportunistic infections. Herpes simplex virus and herpes zoster virus infections were observed in 29 and 16 patients, respectively. No cases of active tuberculosis were observed. The incidence of opportunistic infections in patients aged 50 years or over was significantly higher than that in the other age groups (p = 0.01). The use of steroids (p = 0.02), thiopurine (p < 0.01), and immunosuppressant combination therapy (p < 0.01) was associated with an increased rate of opportunistic infections. However, the use of infliximab was not associated with an increased rate of opportunistic infections (p = 0.62). Multivariate analysis indicated that the use of thiopurine was an independent risk factor for opportunistic infections (p < 0.01).
CONCLUSIONS: Age ≥50 years and the use of immunosuppressants are risk factors for opportunistic infections in patients with IBD. In our cohort, tuberculosis was not seen as a complication of immunosuppressant therapy.

Entities:  

Mesh:

Year:  2012        PMID: 23053426     DOI: 10.1007/s00535-012-0686-9

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  20 in total

Review 1.  Clinical practice. Management of newly diagnosed HIV infection.

Authors:  Scott M Hammer
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

2.  Anti-TNFalpha therapy and vaccination of adults.

Authors:  Paula Duchet-Niedziolka; Zoé Coutsinos; Thomas Hanslik; Odile Launay
Journal:  Joint Bone Spine       Date:  2007-09-19       Impact factor: 4.929

3.  Conception and pregnancy outcome in women with inflammatory bowel disease: A multicentre study from Japan.

Authors:  Makoto Naganuma; Reiko Kunisaki; Naoki Yoshimura; Masakazu Nagahori; Hisae Yamamoto; Hideaki Kimura; Minako Sako; Takaaki Kawaguchi; Masakazu Takazoe; Shojiro Yamamoto; Toshiyuki Matsui; Toshifumi Hibi; Mamoru Watanabe
Journal:  J Crohns Colitis       Date:  2011-03-11       Impact factor: 9.071

4.  Poor recall of prior exposure to varicella zoster, rubella, measles, or mumps in patients with IBD.

Authors:  Makoto Naganuma; Masakazu Nagahori; Toshimitsu Fujii; Junko Morio; Eiko Saito; Mamoru Watanabe
Journal:  Inflamm Bowel Dis       Date:  2013-02       Impact factor: 5.325

Review 5.  Viral prophylaxis in organ transplant patients.

Authors:  Michelle Slifkin; Shira Doron; David R Snydman
Journal:  Drugs       Date:  2004       Impact factor: 9.546

6.  Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study.

Authors:  Stéphane Genevay; Axel Finckh; Adrian Ciurea; Anne-Marie Chamot; Diego Kyburz; Cem Gabay
Journal:  Arthritis Rheum       Date:  2007-05-15

Review 7.  Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments.

Authors:  George Kollias; Dimitris Kontoyiannis
Journal:  Cytokine Growth Factor Rev       Date:  2002 Aug-Oct       Impact factor: 7.638

8.  Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease.

Authors:  Josh Marehbian; H Michael Arrighi; Steve Hass; Haijun Tian; William J Sandborn
Journal:  Am J Gastroenterol       Date:  2009-06-16       Impact factor: 10.864

Review 9.  Prophylaxis of herpesvirus infections in immunocompetent and immunocompromised older patients.

Authors:  Anne-Marie Fillet
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 10.  Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis.

Authors:  N Viget; G Vernier-Massouille; D Salmon-Ceron; Y Yazdanpanah; J-F Colombel
Journal:  Gut       Date:  2008-01-04       Impact factor: 23.059

View more
  35 in total

Review 1.  Oral pathology in inflammatory bowel disease.

Authors:  Miranda Muhvić-Urek; Marija Tomac-Stojmenović; Brankica Mijandrušić-Sinčić
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

2.  Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines.

Authors:  Andrew Wisniewski; Julien Kirchgesner; Philippe Seksik; Cécilia Landman; Anne Bourrier; Isabelle Nion-Larmurier; Philippe Marteau; Jacques Cosnes; Harry Sokol; Laurent Beaugerie
Journal:  United European Gastroenterol J       Date:  2019-11-14       Impact factor: 4.623

3.  Booster influenza vaccination does not improve immune response in adult inflammatory bowel disease patients treated with immunosuppressives: a randomized controlled trial.

Authors:  Hiroko Matsumoto; Satoko Ohfuji; Kenji Watanabe; Hirokazu Yamagami; Wakaba Fukushima; Kazuhiro Maeda; Noriko Kamata; Mitsue Sogawa; Masatsugu Shiba; Tetsuya Tanigawa; Kazunari Tominaga; Toshio Watanabe; Yasuhiro Fujiwara; Yoshio Hirota; Tetsuo Arakawa
Journal:  J Gastroenterol       Date:  2015-02-12       Impact factor: 7.527

4.  Sci-B-VacTM Vs ENGERIX-B Vaccines for Hepatitis B Virus in Patients with Inflammatory Bowel Diseases: A Randomised Controlled Trial.

Authors:  Ohad Etzion; Victor Novack; Yael Perl; Olga Abel; Doron Schwartz; Daniella Munteanu; Naim Abufreha; Gil Ben-Yaakov; Eyal D Maoz; Alex Moshaklo; Vitaly Dizingf; Alex Fich
Journal:  J Crohns Colitis       Date:  2016-02-29       Impact factor: 9.071

Review 5.  Adverse events in IBD: to stop or continue immune suppressant and biologic treatment.

Authors:  Leon P McLean; Raymond K Cross
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2014-02-04       Impact factor: 3.869

Review 6.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

Review 7.  Polycythemia Vera Management and Challenges in the Community Health Setting.

Authors:  Aaron T Gerds; Kim-Hien Dao
Journal:  Oncology       Date:  2017-01-18       Impact factor: 2.935

Review 8.  The Clinical Applications of Endometrial Mesenchymal Stem Cells.

Authors:  Wanyun Zuo; Bingyu Xie; Chenglong Li; Yuhan Yan; Yangyi Zhang; Wei Liu; Jufang Huang; Dan Chen
Journal:  Biopreserv Biobank       Date:  2017-12-21       Impact factor: 2.300

9.  Rates and Predictors of Vaccinations Among Inflammatory Bowel Disease Patients Receiving Anti-Tumor Necrosis Factor Agents.

Authors:  Hung-Viet Pham; Imran Hasan; Natalia Udaltsova; Kathy Pham; Oren Abramson; Mary Anne Armstrong; Debbie Postlethwaite; Dan Li
Journal:  Dig Dis Sci       Date:  2017-08-23       Impact factor: 3.199

Review 10.  Recent trends and future directions for the medical treatment of ulcerative colitis.

Authors:  Makoto Naganuma; Shinta Mizuno; Kosaku Nanki; Shinya Sugimoto; Takanori Kanai
Journal:  Clin J Gastroenterol       Date:  2016-10-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.